Discover More

History of Arthrosamid®

Arthrosamid®’s story started two decades ago. The brainchild of the team at Contura, the product had been in human use for various indications since 2000, and a favourable safety profile had already been established.

Adobe Stock 247947350

An OA treatment 20 years in the making

In April 2021, Arthrosamid® received the CE mark (European market approval) for the symptomatic treatment of patients with knee osteoarthritis (OA), following the completion of a twelve-month prospective open-label study which saw participants experience significant pain reduction.

The CE mark for Arthrosamid® represented a major milestone for a product that has been in development for more than 20 years — and fulfils an unmet clinical need for an effective, long-acting, safe and minimally invasive treatment that may postpone and potentially prevent knee surgery for those with OA. But what’s the backstory behind this novel, non-biodegradable hydrogel that is now expected to provide OA patients with life-changing pain relief and improved mobility?